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SUMMARY
Considerable progress has been made in generating
fully functional and transplantable dopamine neu-
rons from human embryonic stem cells (hESCs).
Before these cells can be used for cell replacement
therapy in Parkinson’s disease (PD), it is important
to verify their functional properties and efficacy in
animal models. Here we provide a comprehensive
preclinical assessment of hESC-derived midbrain
dopamine neurons in a rat model of PD. We show
long-term survival and functionality using clinically
relevant MRI and PET imaging techniques and
demonstrate efficacy in restoration of motor function
with a potency comparable to that seen with human
fetal dopamine neurons. Furthermore, we show
that hESC-derived dopamine neurons can project
sufficiently long distances for use in humans, fully
regenerate midbrain-to-forebrain projections, and
innervate correct target structures. This provides
strong preclinical support for clinical translation of
hESC-derived dopamine neurons using approaches
similar to those established with fetal cells for the
treatment of Parkinson’s disease.
INTRODUCTION
Cell replacement therapy in Parkinson’s disease (PD) is based on
the premise that transplanted midbrain dopamine (DA) neurons
can restore dopaminergic neurotransmission when transplanted
to the DA-depleted striatum, providing a functionally efficient
substitute for the neurons that are lost in the disease. Clinical tri-
als using cells derived from human fetal ventral mesencephalon
(VM) have shown that transplanted DA neurons can functionally
reinnervate the denervated striatum, restore DA release, and at
least in some PD patients, provide substantial long-term clinical
improvement (Barker et al., 2013; Kefalopoulou et al., 2014).
However, the use of tissue from aborted human embryos
presents several ethical and logistical issues that hamper the
effective translation of fetal tissue transplantation as a realistic
therapeutic option.
In order to move to large-scale clinical applications, a readily
available, renewable, and bankable source of cells with the
potential to differentiate into fully functional DA neurons after
transplantation is an absolute requirement. Among the different
stem cell sources available, human pluripotent stem cells, in
particular human embryonic stem cells (hESCs), have advanced
the furthest (Lindvall and Kokaia, 2009; Barker, 2014). Using
protocols entirely based on extrinsic patterning cues that mimic
fetal midbrain development, it is now possible to generate DA
neurons with an authentic midbrain phenotype from human
pluripotent stem cells that survive transplantation and that can
restore motor deficits in animal models of PD (Doi et al., 2014;
Kirkeby et al., 2012a; Kriks et al., 2011).
However, a number of crucial issues need to be addressed in
preclinical studies before these cells can be considered for clin-
ical use: it is important to verify that their functional efficacy is
robust, reproducible, and stable over significant time periods;
that the transplanted cells have the capacity to grow axons
and reinnervate the DA-denervated host striatum over distances
that are relevant for the size of the human brain; and that they
function with equal potency to human fetal VM DA neurons
that have previously been used in clinical trials (Barker, 2014).
Here we have performed a rigorous preclinical assessment of
long-term in vivo functionality and axonal outgrowth capacity of
hESC-derived midbrain DA neurons, critical for their translation
to the clinic. We show long-term survival and functionality using
clinically relevant MRI and positron emission tomography (PET)
imaging techniques and efficacy in restoration of motor function
that is comparable to that seen with human fetal cells. Impor-
tantly, we provide a direct comparison of human DA neurons
sourced from either hESCs or fetal VM and show that hESC-
derived neurons, like their fetal counterparts, can project over
long distances in the lesioned adult rodent brain and regenerate
axonal projections with cell-type specific innervation of correct
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target structures. These data represent an important milestone
in the preclinical assessment of hESC-derived DA neurons and
provide essential support for their usefulness in cell replacement
therapy for PD.
RESULTS
Long-Term Survival and Restoration of Dopaminergic
Neurotransmission by hESC-DA Neurons
First, we wanted to assess long-term survival and function of
grafted cells using methodologies that are used in the clinic.
We therefore transplanted hESC-derived DA (hESC-DA) neurons
to the striatum of 6-hydroxydopamine (6-OHDA) lesioned
athymic, adult rats, allowing for long-term graft survival in the
absence of immunosuppressive treatment. The grafted animals
were followed up to 6 months after transplantation, the point at
which grafts of fetal VM in patients start to become functional
(Piccini et al., 2000). T2-weighed MRI imaging showed surviving
transplants that increased in volume from 1 to 5 months post-
transplantation, indicating initial proliferation and subsequent
maturation of the transplanted cells (Figure S1A available online),
as previously described for transplants of proliferative midbrain
progenitors (Kirkeby et al., 2012a). MR spectroscopy investiga-
tion 5 months postgrafting revealed a high N-acetylaspartic
acid content within the transplanted area, indicative of a
neuron-rich graft (Figures S1B and S1C). Pretransplantation,
the rats were assessed for deficits in striatal dopaminergic
neurotransmission by PET, using 18F-fallypride as a measure of
D2/D3-receptor occupancy (Moon et al., 2010) and
18F-LBT999
as a tracer for the dopamine transporter (DAT) (Dolle´ et al.,
2007) (Figure 1A). In the 6-OHDA-lesioned DA-denervated
striatum 18F-fallypride binding was significantly increased, as
compared with the intact hemisphere, signifying a pronounced
reduction in DA release. After grafting, 18F-fallypride binding
was normalized to intact levels as assessed 5months posttrans-
plantation, indicative of active DA release from the transplanted
hESC-DA neurons (Figures 1A and 1B). Similarly, the near-com-
plete loss of DAT binding, using 18F-LBT999, seen after 6-OHDA
lesion was reversed to around 50% of normal (Figures 1A
and 1C). 18F-DPA714 binding was used to measure microglial
activation (Kuhnast et al., 2012), and no increase was observed
at 5 months postgrafting, relative to the nontransplanted side
(Figure 1A).
Histological Analysis and Innervation Capacity of
hESC-DA Neurons after Intrastriatal Transplantation
Histological analysis confirmed the imaging data, showing
neuron-rich transplants and revealing grafts rich in DA neurons,
expressing both tyrosine hydroxylase (TH) and dopamine trans-
porter (DAT), in the absence of a notable active microglial (Iba1+)
response, overgrowths, or necrotic areas (Figures S2A–S2C). To
assess graft-derived axonal outgrowth we made use of an anti-
body specific for human neural cell adhesion molecule (hNCAM)
(Figures 1D–1G), allowing selective and highly sensitive visuali-
zation of the grafted neurons and their projections. Dense
hNCAM+ innervation was observed throughout the caudate-
putamen, including the dorsolateral striatum, which derives its
innervation exclusively from the A9 neurons of the substantia
nigra (SN) (Figure 1D). Similar innervation was also observed in
other forebrain DA target areas outside the caudate-putamen,
such as nucleus accumbens (NAc) (Figure 1E), olfactory tubercle
(Figure 1D), and the perirhinal and prelimbic cortices (Figures 1F
and 1G), which are essential targets for the A10 neuronal sub-
type, residing in the ventral tegmental area (VTA) (Figures S2D
and S2E).
Taken together, these data prove the ability of hESC-DA neu-
rons to provide extensive reinnervation of the host striatum and
begin to restore DAergic neurotransmission 5 months posttrans-
plantation, using clinically relevant methods to assess graft func-
tion, in the absence of significant adverse events. This is in line
with previous clinical observations using human fetal VM grafted
to patients, where progressive recovery of DA neurotransmission
starts at 6 months, reflecting the gradual maturation of the trans-
planted cells (Piccini et al., 1999, 2000).
Functional Potency Assessment of hESC-DA Neurons
Grafted to the Striatum
We and others have previously shown that hESC-DA neurons
can release DA in vivo (Kirkeby et al., 2012a) and restore a num-
ber of motor deficits in 6-OHDA rodent models of PD when as-
sessed 16–18 weeks after grafting (Kirkeby et al., 2012a; Kriks
et al., 2011). However, these transplants contained 15,000–
18,000 hESC-derived DA neurons, and the high cell number
makes it difficult to estimate the efficacy of the cells (Barker,
2014). In previous preclinical and experimental studies using
grafts of human fetal VM, it has been shown that normalization
of amphetamine-induced rotation after intrastriatal transplanta-
tion can be achieved with an average number of 1,200 surviving
TH+ neurons (Brundin et al., 1986). On the basis of this informa-
tion, we performed a potency experiment designed to deter-
mine the minimal number of hESC-DA neurons capable of
inducing functional recovery in the amphetamine-induced rota-
tion test. We transplanted 6-OHDA lesioned rats, aiming for at
least a 10-fold lower number of hESC-DA than the grafts func-
tionally assessed in earlier studies (Kirkeby et al., 2012a; Kriks
et al., 2011). The rats were pretested to confirm the complete-
ness of the lesion and immunosuppressed with daily injections
of ciclosporin for 18 weeks. At this time point, the rats showed
a significant recovery in amphetamine-induced rotation (Fig-
ure 2A: t4 = 6.76, p < 0.01; n = 5), despite a much lower number
of TH+ neurons in the grafts (Figures 2B and 2C). Quantifica-
tions showed that the average number of surviving TH+ neurons
was 986 ± 333 per rat (n = 5). Two of the rats had less than 500
surviving hESC-DA neurons and yet showed a complete
reduction in rotational bias (Figure 2B). Within TRANSERUO,
a EU-funded research consortium formed to develop an
efficacious and safe treatment methodology for PD using fetal
cell based treatments (http://www.transeuro.org.uk), research
groups including our own have optimized and standardized tis-
sue preparation protocols across several centers throughout
Europe. A recent report with cells prepared using this protocol
show that a significant reduction in amphetamine-induced
rotation could be achieved with transplants of human fetal
VM with as few 657 ± 199 surviving TH+ neurons (Rath et al.,
2013). These results indicate that the functional potency
of grafted hESC-DA neurons is on par with that of human DA
neurons obtained from fetal VM (Brundin et al., 1986; Rath
et al., 2013).
Cell Stem Cell
Preclinical Validation of hESC-Derived DA Neurons
654 Cell Stem Cell 15, 653–665, November 6, 2014 ª2014 The Authors
18
F-
LB
T9
99
m
ea
n
 r
at
io
 ip
si/
co
nt
ra
m
ea
n
 [9
0-
11
0]
1.0
0.8
0.6
0.4
0.2
0
5M post-
grafting
*
6-OHDA
lesion
A 18F-Fallypride PET
D2-binding
18F-Fallypride
Binding ratio lesion/intact
18F-LBT999
Binding ratio lesion/intact
MRI
6-
O
H
D
A
 le
si
on
5M
 p
os
t-g
ra
fti
ng
18F-LBT999 PET
DAT binding
18F-DPA714 PET
Microglial activation
lesionintact
DB
C
E
F G
AC
AC
CPu
AC
AC
NAc
PrL
PrL
FM
FM
T
T TT T
hNCAM
E
G
SUV [0-0.08] SUV [0-0.07] SUV [0-0.05]
18
F-
Fa
lly
pr
id
e
m
ea
n
 r
at
io
 ip
si/
co
nt
ra
m
ea
n
 [9
0-
11
0]
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
5M post-
grafting
*
6-OHDA
lesion
Figure 1. Functional Imaging of Long-Term Surviving Intrastriatal Transplants of hESC-DA Neurons
(A) MRI and PET scans for 18F-fallypride, 18F-LBT999 after 6-OHDA lesion, show an increase in binding of 18F-fallypride (n = 6) on the side of lesion indicating
an impaired DA release, confirmed by a loss of 18F-LBT999 (n = 7) binding due to loss of DAT binding sites. At 5 months posttransplantation both 18F-fallypride
(n = 11) and 18F-LBT999 (n = 14) binding are restored toward normal, indicative of a graft rich in functional DA neurons, in the absence of any detectable microglial
response, as assessed with 18F-DPA714 (n = 13).
(B) Quantitative measurements of binding ratios between intact and lesioned striatum revealed an increased binding potential of 18F-fallypride in the 6-OHDA
denervated striatum, which was normalized to intact levels 5 months posttransplantation of hESC-DA neurons.
(C) A 6-OHDA lesion resulted in a near complete loss of 18F-LBT999 binding due to the loss of DAT-expressing dopaminergic terminals, which was restored
toward normal posttransplantation.
(D and E) Immunohistochemistry of hNCAM revealed neuron-rich grafts of hESC-DA neurons 6months posttransplantation, providing extensive innervation of the
host CPu and surrounding extrastriatal dopaminergic targets, such as NAc.
(F and G) Away from the graft core, widespread innervation by human axons was found in known DA target structures within the prefrontal cortex.
See also Figure S1. AC, anterior commissure; CPu, caudate-putamen unit; FM, forceps minor; NAc, nucleus accumbens; PrL, prelimbic cortex; T, transplant. In
(B) and (C), data are represented as mean ± SEM. *p < 0.01. In (A), (D), and (F), scale bars represent 1 mm. In (E) and (G), scale bars represent 0.5 mm.
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Histological Comparison of DA Neurons Sourced from
Human Fetal VM and hESCs after Intrastriatal
Transplantation
We next performed a direct histological comparison between
hESC-DA neurons and authentic human fetal DA neurons pre-
pared according to Rath et al. (2013), grafted in parallel, in order
to validate the morphology, maturation, and phenotypic proper-
ties of the transplanted DA neurons (Figures 2D and 2E). In this
analysis, we observed the presence of TH+ neurons with two
distinct morphologies in the hESC-grafted animals (Mendez
et al., 2005; Thompson et al., 2005): A9-like nigral neurons char-
acterized by large angular somata andA10-like VTA neuronswith
small, round somata (Figure 3A). The morphology of the hESC-
derived neurons was identical to that observed with intrastriatal
transplants of fetal VMwhenanalyzedat 6monthsposttransplan-
tation (Figure 3C) and consistent with graft appearance from
previous postmortem reports from transplanted PD patients
(Mendez et al., 2005). When staining the cells for markers
commonly used to distinguish between SN (A9) and VTA (A10)
neurons, TH+ neurons expressing GIRK2 (A9), Calbindin (A10),
or both markers were readily detected (Figures 3B and 3D).
Quantifications showed that TH+/GIRK2+ neurons were the
most abundant subtype in both hESC-derived and fetal grafts
(Figure 3I) and that the proportion was similar in both hESC-
and fetal-derived grafts (Figure 3J). Taken together, this analysis
shows that hESC-DA neurons are indistinguishable from their
fetal counterparts on the basis of graft appearance, morphology,
andmarker expression6monthsafter grafting and that thehESC-
derived grafts are rich in both A9-like and A10-like DA neurons.
Long-Distance Axonal Outgrowth of hESC-Derived
Neurons after Transplantation into the Substantia Nigra
When assessing the cells for their suitability to be used in clinical
trials, it is important to keep in mind that the human brain is a
much larger structure than the rodent brain and that it is neces-
sary for the transplanted cells to extend axons over long dis-
tances in order to sufficiently reinnervate the putamen in patients.
We therefore sought to create an assay through which long-dis-
tance, target-specific outgrowth could be assessed in an adult
rodent model of PD that would be predictive when translating
to the larger human brain. Intrastriatal grafting, the standard
used in preclinical andclinical studies, places thecellswithin their
main target structure, thus making it difficult to assess the full
innervation capacity of human cells when grafted to the rat brain.
To investigate the ability of hESC-DA neurons to innervate
specific structures across longer distances, we employed a ho-
motopic grafting approach where we transplanted hESC-DA
neurons into the lesioned SN, instead of the traditional ectopic
placement in the striatum. Transplants of fetal VM served as an
important reference to see if hESC-derived neurons could match
their capacity for long-distance and target-specific innervation.
When grafted to the SN, both hESCs and fetal VM gave rise to
grafts rich in TH+ neurons expressing GIRK2 and Calbindin with
morphologies indistinguishable from cells grafted to the striatum
(compare Figures 3E–3H with Figures 3A–3D). In the majority of
rats with fetal VM transplants (n = 7/8), we observed neuron-rich
grafts, discretely placed within the host SN, extending large
numbers of hNCAM+ axons rostral along the medial forebrain
bundle (MFB) and the adjacent nigrostriatal pathway, assembled
in a well-defined and fasciculated tract (Figures 4A, 4G, 4I, S3A,
and S3B). Rostral extending axonal bundles were seen to defas-
ciculate and ramify within their terminal target fields, providing
widespread innervation of specific host structures throughout
the forebrain (Figure 4A), extending more than 10 mm from the
graft core. hNCAM+ terminal innervation was particularly dense
in caudate-putamen (Figure 4C), NAc (Figure 4D), amygdala (Fig-
ure 4B), and perirhinal and anteromedial frontal cortices (Figures
4A and 4E).
10
6
8
4
2
0
Lesion Control
hESC
**
A
m
ph
et
am
in
e 
ro
ta
tio
ns
(N
et 
tur
ns
/m
inu
te)
Equipotency assay: function Equipotency assay: cell counts
pre-
transpl.
16 weeks
post-transpl.
0
500
1 20
1000
1500
2000
2500
TH
+
 
ce
ll 
co
un
ts
Rotations post-transpl.
TH
E Fetal
-Intrastriatal
TH
TH
B CA
D hESC
-Intrastriatal
Equipotency Figure 2. Functional Equipotency of Intra-striatal Transplanted hESC-DA Neurons
and Comparable Morphology to Grafts of
Fetal VM-Derived DA Neurons
(A) 6-hydroxydopamine lesioned rats displayed
a strong unilateral rotational bias upon adminis-
tration of amphetamine, which was significantly
normalized 16 weeks after intrastriatal trans-
plantation of hESC-DA neurons (white bars, n = 5),
whereas lesion controls (black bars, n = 6), not
receiving any transplant, showed no significant
changes when monitored in parallel.
(B) Estimation of the number of surviving TH+
neurons within the graft revealed a relatively low
number that gave rise to graft-mediated functional
recovery.
(C) Histological analysis revealed grafts with
sparse numbers of TH+ neurons dispersed
throughout.
(D and E)When comparing transplants of hESC-
derived (D) and fetal-derived (E) DA neurons
6 months posttransplantation, both groups re-
vealed grafts rich in DA neurons that are indistin-
guishable on a gross morphological level.
See also Figure S2. TH, tyrosine hydroxylase.
In (A), data are represented as mean ± SEM. **p <
0.01. In (C)–(E), scale bars represent 100 mm.
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Notably, graft-derived hNCAM+ glial cells were detected in the
transplants derived from the 8-week-old fetus (Figures 4F and
4G), but not from the younger 5.5-week-old fetus (Figures 4H
and 4I). In the grafts of 8-week fetal VM, the graft-derived glial
cells could be traced along myelinated and nonmyelinated fiber
tracts, accompanying the hNCAM+ axons up to the level of the
caudal caudate-putamen (Figure 4G), as described in previous
xenografting studies (Gates et al., 1998; Isacson et al., 1995;
Pundt et al., 1995). Despite the absence of graft-derived glia in
the transplants of the younger embryo (Figure 4H), hNCAM+ fiber
outgrowth was comparable to grafts derived from older tissue
(Figures S3B–S3G). This observation indicates that the extent
and patterning of axonal outgrowth is largely independent of
this glial population present within the transplant.
Six months posttransplantation we observed robust survival in
all hESC grafted animals (n = 8/8), with no signs of overgrowth or
necrosis, similar inmorphology to the intrastriatal grafts of hESC-
DA neurons described above (Figures 1, 2D, and S2A–S2C). As
observed with intranigral transplants of fetal VM, large numbers
of hNCAM+ fibers projected rostral along the MFB and the adja-
cent nigrostriatal pathway (Figures 5A, 5F, S4A, and S4B). The
axons extending along the MFB continued a distance more
than 10 mm from the graft core and gave rise to dense terminal
networks in amygdala (Figure 5B); dorsolateral striatum (Fig-
ure 5C) and piriform cortex; ventral striatum, including NAc (Fig-
ure 5D); olfactory tubercle; lateral septum; and large parts of the
frontal lobe (Figures 5A, 5E, and 5G). hNCAM+ cells with a glial
morphology were not detected in any of the hESC-grafted rats,
consistent with our hypothesis that they are not essential for
extensive axonal outgrowth.
Subtype Identity and Target-Specific Innervation of
hESC-DA Neurons after Transplantation into the
Substantia Nigra
Although A9 and A10 midbrain DA neuron subtypes can be arbi-
trarily distinguished on the basis of morphology and GIRK2/Cal-
bindin protein expression, true identification of the subtype is
linked to the ability of the neurons to innervate their appropriate
forebrain targets: the A9 preferentially innervating the caudate-
putamen and A10 neurons innervating limbic and cortical areas,
including ventral striatum andNAc. To determine the presence of
authentic A9 or A10 subtypes in grafts of fetal VM and hESC-DA
neurons, we performed quantitative fiber density measurements
(Figures S5A and S5B) of human hNCAM+ axons (Figure 6C) in
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in Long-Term Grafts of hESC-DA Neurons and Human Fetal VM
(A) Upon close inspection, hESC-DA neurons gave rise to TH+ dopaminergic
neurons with an A9-like neuron morphology, characterized by large angular
somas (upper panel), as well as A10-like neurons with small, round somas
(lower panel).
(B) The presence of neurons coexpressing TH and GIRK2 (red and green) and
TH and Calbindin (red and blue) indicates that both midbrain DA neuron
subtypes, A9 and A10, were contained in grafts of hESC-derived neurons.
(C and D) Intrastriatal grafts of human fetal VM contained TH+ dopami-
nergic neurons with A9 and A10 morphologies, coexpressing GIRK2 and/or
Calbindin.
(E and F) Homotopic placement of hESC-DA neurons in SN resulted in large
numbers of TH+ dopaminergic neurons with mature A9 and A10morphologies,
confirmed by coexpression of TH with GIRK2 and Calbindin, respectively.
(G and H) Fetal VM tissue grafted to the SN displayed the same ability to
generate transplants with dopaminergic neurons of A9 and A10 morphologies
and protein expression (H).
(I and J) The number and proportion (J) of TH+ neurons, coexpressing GIRK2,
Calbindin, or both markers, was quantified in all groups (n = 3 per group).
Calb, Calbindin; GIRK2, G protein-regulated inward-rectifying potassium
channel 2; TH, tyrosine hydroxylase. In (I) and (J), data are represented as
mean ± SEM. In (A), (C), (E), and (G), scale bars represent 50 mm. In (B), (D), (F),
and (H), scale bars represent 20 mm.
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defined striatal areas (A9 targets), as well as limbic and cortical
areas (A10 targets), as depicted in Figure S5C.We found that
the number of axons projecting rostral was similar in the VM
(2,169 ± 181; n = 3) and hESC (2,453 ± 774; n = 4) groups. Over-
all, the fiber density measurements showed that the midbrain-
patterned hESCs exhibited the same A9/A10 target specificity
and axonal outgrowth patterns as human fetal VM cells. Both
fetal VM- and hESC-derived neurons innervated the caudate-pu-
tamen, which in the rat is targeted almost exclusively by A9 neu-
rons, but that fetal VM tissue was more efficient at innervating
the dorsolateral caudate-putamen (Figure 6A: dorsomedial,
t25 = 2.69, p < 0.01; dorsolateral, t25 = 4.38, p < 0.0001; Medial,
t25 = 2.14, p < 0.05). All A10-specific target structures were inner-
vated at similar densities by fetal VM and hESCs, with the excep-
tion of the infralimbic cortex and septum, which received a more
pronounced innervation from the hESC grafts (Figure 6B: ILC,
t25 = 5.99, p < 0.0001; Sept, t25 = 5.32, p < 0.0001).
In order to identify the specific contribution from grafted
DA neurons, we utilized immunofluorescence to detect human
axons coexpressing TH and hNCAM (Figure 6F). Performing
fiber density counts on double-positive fibers; we again found
that fetal- and hESC-derived DA neurons demonstrated a similar
propensity to innervate A9 and A10 specific striatal target
structures (Figures 6D and 6E), although A9-specific innervation
derived from fetal VM grafts was overall of higher density (Fig-
ure 6D: dorsomedial, t4 = 2.27, p < 0.05; dorsolateral, t4 = 4.15,
p < 0.01).
In summary, midbrain-patterned hESCs exhibited the same
remarkable ability as their fetal counterparts to extend axons
over long distances and provide specific innervation of the rele-
vant A9 and A10 host target structures. GIRK2 and Calbindin
are commonly used as subtype markers for stem cell-derived
DA neurons in vitro and after transplantation (Kirkeby et al.,
2012a; Kriks et al., 2011; Ryan et al., 2013). However, we notice
here that a high GIRK2+ component (Figures 3I and 3J) does not
directly translate to a strong innervation of the A9 target struc-
tures (Figures 6A and 6D). This observation is supported by
the postmortem analysis of the adult human midbrain, which re-
veals that colocalization of TH and GIRK2 occurs in all DAergic
neurons of the SN, but also in a substantial portion of DAergic
neurons of the VTA (Reyes et al., 2012), thus calling for a
more stringent analysis of A9 subtype of stem cell-derived DA
neurons.
Expression of OTX2 Alters the Axonal Outgrowth
Pattern of Transplants of hESC-Derived Neurons
Next, we sought to investigate if target-specific axonal
outgrowth from hESC-DA neurons is a cell intrinsic property
that can be regulated by transcriptional programming. Exper-
iments in mice have established a major role for the tran-
scription factor Otx2 in the development of the midbrain DA
progenitors. The expression of this transcription factor is main-
tained selectively in DA neurons with a mature A10 phenotype,
where it acts to control the pattern of axonal outgrowth in fore-
brain structures (Chung et al., 2010, 2005; Di Salvio et al.,
2010a, 2010b). We generated transgenic hESCs (OTX2-
hESCs) using a lentiviral construct that expresses OTX2 at
physiologically relevant levels under the control of the PGK
promoter and contains miRNA-292 target sequences to
restrict expression to differentiated progeny (Sachdeva et al.,
2010) (Figures S6A and S6B). We verified that the transgene
did not disturb patterning toward a midbrain fate, as OTX2-
hESCs gave rise to a similar number of LMX1A, FOXA2, and
OTX2 expressing progenitors, as compared with wild-type
(WT) hESCs (compare Figures S6D and S6E with Figures
S4C and S4D). At a later time point in vitro, and consistent
with the emergence of mature TH+ neurons, OTX2 was down-
regulated in mature MAP2+/TH+ neurons from parental WT
hESCs, but specifically maintained in differentiated OTX2-
hESCs (Figures S6C and S6F). The OTX2-hESC-derived DA
neuron progenitors were transplanted to the SN of 6-OHDA-
lesioned athymic rats (n = 8). At 6 months, immunohistochem-
ical analysis revealed a pronounced expression of OTX2 within
the graft core at a level exceeding that observed in grafts
of fetal VM and WT hESCs (Figures S6G–S6I). The OTX2-
hESC grafts exhibited a similar axonal outgrowth pattern to
the WT hESCs, with large numbers of hNCAM+ axons extend-
ing rostral within the MFB (Figures 7A and 7B). However,
the innervation derived from the OTX2-hESCs was restricted
almost exclusively to A10 target structures, including NAc;
ventral striatum; septum; amygdala; and antero-medial re-
gions of the prefrontal cortex (Figures 7A–7E and S6K). Few,
if any, hNCAM+ fibers were observed in A9 target structures,
such as dorsolateral caudate-putamen (Figures 7A and 7C).
When quantifying the innervation of all measured A9 structures
(dorsomedial, dorsolateral, medial, and central aspects of the
caudate-putamen unit; Figure S5C), OTX2-hESCs displayed
a reduced preference for innervating A9 target structures
both when compared with grafts of the parental hESCs and
with fetal-derived DA neurons (Figure 7H: F(2, 105) = 28.91,
p < 0.0001; difference confirmed using a Tukey’s post hoc
test, p < 0.001).
To exclude that this dramatic switch in target innervation was
due to experimental variation or altered in vitro patterning, we
replicated this experimentwith a newcell differentiationand trans-
planted to immunocompetent rats under immunosuppression
Figure 4. Extent and Pattern of Axonal Outgrowth from Intranigral Transplants of Human Fetal VM 6 Months Posttransplantation
(A) Schematic overview of hNCAM+ fibers from an intranigral transplant of fetal VM, innervating the host brain as visualized under dark-field illumination of DAB-
developed sections (see Figure S3A).
(B–E) Transplants of fetal VM displayed a strong preference for innervating: amygdala (including MeA and BLA) (B); dorsolateral caudate-putamen (C); and
nucleus accumbens, NAc (D). Graft-derived axons were found as far as 10 mm away from the graft core in areas of the prefrontal cortex (E).
(F–I) In bright-field illumination, the appearance of the8-week (F) and5.5-week (H) donor transplants and the associatedoutgrowthof hNCAM+axons in theMFBand
the adjacent nigrostriatal pathway (G and I), including the presence of migrating hNCAM+ graft-derived glial cells in the older donor transplants (Insets in F and G).
See also Figure S3. AC, anterior commissure; BLA, basolateral amygdala; CPu, caudate-putamen; FM, forceps minor; IC, internal capsule; MeA, medial
amygdaloid nucleus; MFB, medial forebrain bundle; NAc, nucleus accumbens; NSP, nigrostriatal pathway; p.c., postconception; PrL, prelimbic cortex; T,
transplant. In (B), (D), (F), (G), (H), and (I), scale bars represent 0.2 mm. In (C) and (E), scale bars represent 0.5 mm.
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using daily injections of ciclosporin. In all animals (n = 7/7; 14-
week survival), grafts of OTX2-hESCs were efficiently differenti-
ated into mature TH+ neurons (Figure S6J), and the identical
pattern of A10-specific target innervation was observed (Figures
7F and 7G).
These findings provide evidence that target-specific
outgrowth, attributed to a given midbrain DA neuron subtype,
can be controlled and redirected in hESC-derived cell prepara-
tions, thus providing an opening for future efforts to enhance
the fiber outgrowth to specific target nuclei.
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Figure 5. Overview of Neuronal Outgrowth of Intranigral Transplants of hESC-DA Neurons 6 Months after Transplantation
(A) Schematic overview of hNCAM+ fiber outgrowth from an intranigral transplant of hESC-DA neurons, as visualized under dark-field illumination of DAB-
developed sections (see Figure S4A).
(B–D) Higher magnification illustrates the hESC-derived innervation patterns of the amygdala (B), caudate-putamen (C), and NAc (D).
(E–G) hNCAM+ fiber bundles were seen to extend rostral within the MFB and nigrostriatal pathway (E), and also within the myelinated white matter tracts of the
internal capsule (F), over a distance of more than 10 mm from the graft core to innervate parts of the prefrontal cortex (E and G).
See also Figure S4. AC, anterior commissure; BLA, basolateral amygdala; CeA, Central Amygdaloid nucleus; CPu, caudate-putamen unit; FM, forceps minor; IC,
internal capsule; MeA,medial amygdaloid nucleus; MFB,medial forebrain bundle; NAc, nucleus accumbens; NSP, nigrostriatal pathway; PrL, prelimbic cortex; T,
transplant. In (B)–(G), scale bars represent 0.5 mm.
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DISCUSSION
In this study, we have performed a comprehensive preclinical
validation of hESC-derived DA neurons that fully supports their
functional efficacy and capacity for long-distance, target-spe-
cific reinnervation, predictive of their therapeutic potential.
Using imaging techniques previously used to assess graft
function in patients (Kefalopoulou et al., 2014; Piccini et al.,
1999), we demonstrate that hESC-DA neurons survive, mature,
and restore DA neurotransmission in the denervated striatum
for up to 6 months postgrafting. When compared side-by-side
with their fetal counterparts, the hESC-DA neurons appear iden-
tical in terms of morphology and marker expression, supporting
their authenticity and stable phenotype. Importantly, we have
also performed an equipotency assay, establishing that the
hESC-DA neurons can completely reverse motor asymmetry in
the drug-induced rotation test in numbers more than 10-fold
lower than previously used (Kirkeby et al., 2012a; Kriks et al.,
2011) and at a dose, i.e., a threshold number, of around 1,000
surviving DA neurons, similar to that seen with human fetal VM
tissue (Brundin et al., 1986; Rath et al., 2013). Knowing that the
number of surviving fetal DA neurons in a transplanted patient
needs to be at least 100,000 in order to achieve a good clinical
outcome (Hagell and Brundin, 2001), the equipotency data
presented here will be important for guiding cell dosage when
designing the first-in-man trial with hESCs.
We show that midbrain-patterned hESCs transplanted homo-
topically to the SN exhibit the same remarkable ability as their
fetal counterparts to project axons over long distances in the
adult brain, providing highly specific and appropriate innervation
of midbrain DA target structures in the forebrain (Isacson et al.,
1995; Wictorin et al., 1992). Intriguingly, and of clinical impor-
tance, this extensive axonal outgrowth occurs in the adult brain.
While other reports have previously described long-distance
outgrowth from transplants of hESC-derived neurons, these
studies have been performed in neonatal rats andmice (Denham
et al., 2012; Espuny-Camacho et al., 2013) and have not used
hESCs patterned toward a specific dopaminergic fate. The ca-
pacity of the hESC-DA neurons to reinnervate previously dener-
vated forebrain targets when transplanted to the SN is unparal-
leled and matched well the axonal outgrowth patterns obtained
from grafts of authentic human fetal midbrain DA neurons.
Clinical studies show that grafts of fetal VM-derived DA neu-
rons, transplanted to the DA-deficient putamen, can restore
DA neurotransmission and provide functional benefits that are
sustained over many years (Barker et al., 2013; Kefalopoulou
et al., 2014). From preclinical studies we know that the efficacy
of intrastriatal DA neuron grafts depends not only on the number
of surviving DA neurons but also on their phenotype and their ca-
pacity to reinnervate a major part of the denervated target. We
show here that the hESC-DA neurons generated by the current
protocol are of the correct midbrain phenotype and contain the
two major A9 and A10 DA neuron subtypes, similar to fetal VM
grafts. This phenotype provides the grafts with the capacity to
reinnervate both striatal and extrastriatal midbrain DAergic
target structures. Importantly, we show that hESC-DA neurons
are functionally equipotent to fetal VM neurons when grafted
to the striatum and their axonal growth capacity matches that
achieved by fetal VM neurons when grafted to the striatum and
the SN. Data from transplantation studies in rodents and human
autopsy cases indicate that DA neurons from human fetal VM
have the capacity to extend axons for up to 5–7 mm in the
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Figure 6. Quantitative Analysis of Neuronal
Fiber Density in A9 and A10 Target Struc-
tures Derived from Intranigral Grafts
(A) Fetal VM grafts showed greater affinity to
A9 targets in caudate-putamen (dark gray bars;
n = 4) than to hESC-DA neurons (light gray bars;
n = 4).
(B) Fetal VM and hESC-DA neurons were equally
capable of innervating A10 targets, including
NAc, olfactory tubercle, and cingulate cortex,
while infralimbic cortex and septum received
denser innervation from hESC-DA neurons.
(C) Example of a fiber density measurement
performed on hNCAM immunostained sections.
(D) Colabeling with TH and hNCAM showed that
both fetal VM and hESC-DA neurons were able
to innervate the caudate-putamen, although DA
neurons derived from fetal VM showed a stronger
preference for the dorsal caudate-putamen than
those derived from hESCs.
(E) TH+/hNCAM+ fibers were observed in all A10
targets innervated by fetal VM transplants (black
bars; n = 3). hESC-derived TH+/hNCAM+ fibers
were dense in NAc and olfactory bulb, but absent
in cortical areas (white bars; n = 4).
(F) Confocal image of TH+/hNCAM+ section used
for quantification.
See also Figure S5. CingC., cingulate cortex; Dors.
lat., dorsolateral; Dors. med., dorsomedial; ILC,
infralimbic cortex; MFB, medial forebrain bundle; NAc core, nucleus accumbens, core; Olf. tub., olfactory tubercle; Sept, septum. In (A), (B), (D), and (E), data are
represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.0001. In (C) and (F), scale bars represent 10 mm.
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Figure 7. Maintained Expression of OTX2 in hESC-Derived Neurons Results in an Altered Axonal Outgrowth Pattern
(A) Schematic overview of the pattern of hNCAM+ axonal outgrowth derived from intranigral grafts of OTX2-hESCs 6 months posttransplantation, as visualized
under dark-field illumination of DAB-developed sections (see Figure S6K). These cells displayed a strong preference for A10 target structures, such as septum,
cingulate, prelimbic, and infralimbic cortices.
(B) The majority of axons extended rostral within the MFB, along both gray and white matter, with few axons innervating amygdala.
(C) Only rare hNCAM+ axons were observed in caudate-putamen, the prime A9 target structure.
(D and E) Maintained expression of OTX2 did not alter the long-distance growth capacity of the grafted neurons, as a dense fiber network was observed in both
septum and NAc, as well as in prelimbic cortex.
(legend continued on next page)
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striatum, which makes it possible to reinnervate a major part
of the human putamen with a limited number of cell deposits
(Freeman and Brundin, 2006; Kordower et al., 1995). The axonal
outgrowth observed here, up to 10 mm from the graft deposit,
indicates that the growth capacity of the hESC-derived DA neu-
rons will be sufficient to provide efficient and widespread resto-
ration of DA neurotransmission in the DA-denervated striatal
targets in PD patients. The potency of the hESC-derived DA
neurons, with respect to functional efficacy and long-distance
targeted reinnervation, is on par with that of fetal VM cells, which
provides important support for their therapeutic potential and
use for cell replacement therapy in PD.
EXPERIMENTAL PROCEDURES
Research Animals
All procedures were conducted in accordance with the European Union
Directive (2010/63/EU) and were approved by the ethical committee for the
use of laboratory animals at Lund University and the Swedish Department of
Agriculture (Jordbruksverket), as well as French legislation.
Athymic, nude rats were housed in individual ventilated cages, under a 12 hr
light/dark cycle with ad libitum access to sterile food and water. Sprague-
Dawley rats were kept in similar conditions as above, but in standard cages.
Experimental Design for Functional Imaging Experiment
Adult (<1 year) male, athymic, nude rats (Crl:NIH-Foxn1rnu) were purchased
from Charles River and used as graft recipients in all experiments and controls
(n = 20). All rats received a 6-hydroxydopamine lesion of the medial forebrain
bundle and 2 weeks later were assessed for lesion efficacy using amphet-
amine-induced rotations. All animals received longitudinal follow using MRI.
The animals were stratified to the follow groups: baseline PET scanning,
with subsequent follow-up scans at 5 to 6 months posttransplantation
(n = 14), and MR spectroscopy of the grafts (n = 9).
Experimental Design for Circuit Reconstruction and Equipotency
Experiments
Adult (<180 g) female, athymic, nude rats (Hsd:RH-Foxn1rnu) were purchased
from Harlan Laboratories and used as graft recipients and controls (n = 51).
For repetition of the OTX2-overexpression and equipotency experiments,
female Sprague-Dawley rats (225–250 g) were purchased from Charles
River (n = 14 and n = 5, respectively). All surgical procedures, such as
anesthetic doses, etc., were performed as described in detail (Grealish
et al., 2010).
All rats received a 6-hydroxydopamine lesion of the medial forebrain bundle
and 2 weeks later were assessed for lesion efficacy using amphetamine-
induced rotations. The animals were stratified to the follow groups: intranigral
grafting of fetal ventral mesencephalon (n = 8); intranigral grafting of hESC-
derived DA neurons (n = 8); intranigral grafting of OTX2-hESCs, nude rats
(n = 8), Sprague-Dawley rats (n = 14); equipotency intrastriatal grafting of
hESC-derived DA neurons (n = 5); intrastriatal grafting of fetal tissue (n = 4);
and lesion controls (n = 6).
Amphetamine-Induced Rotation
Rotational bias, after systemic amphetamine challenge (2.5mg/kg, intraperito-
neally; Apoteksbolaget), was recorded using an automated system (Omnitech
Electronics). The animals were recorded for 90 min, and only full body turns
were counted and then expressed as net turns per minute, with rotations
toward the side of the lesion given a positive value. Only animals with more
than 5 turns per minute were considered successfully lesioned.
Differentiation of hESCs
Human ESCs H9 (WA09, passages 31–45) were differentiated to a ventral
midbrain fate, using the protocol as described in detail in Kirkeby et al.
(2012b) and Supplemental Experimental Procedures.
Human Fetal Tissue
Human fetal tissue was obtained from legally terminated embryos with
approval of the Swedish National Board of Health and Welfare in accor-
dance with existing guidelines including informed consent from women
seeking elective abortions. The gestational age of each embryo was deter-
mined by measuring the crown-to-rump length and/or estimated by ultra-
sound measurements. Embryos were then staged according to weeks
postconception.
Transplantation Procedure
hESCs were prepared for transplantation as in Kirkeby et al. (2012a), while
fetal tissue was prepared and transplanted as a semicrude suspension, as
described in Rath et al. (2013).
Magnetic Resonance and PET Imaging
All specifications of these procedures are detailed in Supplemental Experi-
mental Procedures.
Immunohistochemistry
All samples, cultured cells and brain tissue, were fixed in fresh 4% paraformal-
dehyde. A complete list of suppliers and concentrations of primary and sec-
ondary antibodies used is detailed in Supplemental Experimental Procedures.
Fiber Density Measurements
Quantitative analysis of the density of human fibers innervating specific areas
was performed using a stereological method (Mouton et al., 2002). Details
of sampling and acquisition are described in Supplemental Experimental
Procedures.
Statistical Analysis
All data are presented as mean ± SEM.
Statistical tests and biological replicates are stated in results or in the figure
legends. All statistical analyseswere performed usingGraphPadPrism v6.0 for
Mac OS X. An alpha level of p < 0.05 was set as a threshold for significance.
In Figures 1B and 1C an unpaired t test was used to compare the baseline
after 6-OHDA lesion and 5 months posttransplantation. In Figures 6A, 6B,
and 6D, all fiber density was analyzed using a one-tailed unpaired t test. In
Figure 7H the innervation of A9 structures in the OTX2-hESC group was
compared with the hESCs and fetal VM grafted groups using a one-way
ANOVA, with differences between groups confirmed using a Tukey’s post
hoc. The behavioral data in Figure 2A were analyzed with a two-tailed paired
t test.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.stem.2014.09.017.
(F and G) In a repeat of this experiment in ciclosporin-treated rats, we confirmed that fiber outgrowth from OTX2-hESCs was confined almost exclusively to A10
target areas, such as NAc and septum (F) and prelimbic cortex (G). Notably, this outgrowth pattern was observed as early as 14 weeks after transplantation.
(H)OTX2-hESCs have a significantly impaired ability to extend hNCAM+ axons into A9 structures as compared with hESC and fetal grafts (all groups n = 3 animals
with triplicate measures in four structures).
See also Figure S6. AC, anterior commissure; BLA, basolateral amygdala; CPu, caudate-putamen unit; FM, forceps minor; IC, internal capsule; MeA, medial
amygdaloid nucleus; MFB, medial forebrain bundle; NAc, nucleus accumbens; OT, Olfactory Tract; PrL, prelimbic cortex; Sept, septum; T, transplant. In (H), data
are represented as mean ± SEM. **p < 0.001
In (B)–(G), scale bars represent 0.5 mm.
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